Investigators presented findings from the CLEAR study at the 40th Annual European Association of Urology (EAU) Congress in Madrid. Results showed better early patient satisfaction and sexual function with UroLift compared to Rezūm water vapor therapy. Boston Scientific has marketed the Rezūm therapy since its 2018 acquisition of NxThera.
CLEAR marks the first head-to-head randomized controlled trial comparing early patient outcomes following treatment with UroLift and Rezūm. Teleflex said the study provides critical insights into patient experience, safety and efficacy. It could help physicians and patients make informed treatment decisions.
The study had a primary endpoint of catheter independence between three and seven days post-procedure. Additional endpoints looked at patient satisfaction, sexual function and the impact of the procedure on daily activities. That included discomfort from pain or bleeding during urination.
Among the 37 patients treated with Rezūm, 10 failed to achieve catheter independence within the target timeframe. Investigators reported one of the 42 UroLift patients failing to reach this benchmark. More patients treated with Rezūm reported interference in daily activities due to pain while urinating and blood in urine, Teleflex said. These effects persisted at 14 days and one month post-procedure.
Sexual function outcomes favored UroLift, too, the company said, as did overall patient satisfaction. UroLift patients consistently rated their experience more favorably, according to Teleflex.
“Comparative clinical trials play a crucial role in guiding treatment decisions for benign prostatic hyperplasia by providing clear, evidence-based insights into safety, efficacy, and patient experience,” said Dr. Matt Ashley, associate medical director at Teleflex. “Understanding how these therapies perform not only in clinical settings but also in real-world patient recovery is essential. At Teleflex, we are committed to advancing research that supports the UroLift™ procedure as a trusted, patient-preferred option for BPH symptom treatment.”
